We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

International Stem Cell Alliance

By Biotechdaily staff writers
Posted on 23 May 2002
An agreement involving the distribution of human embryonic stem cell lines has been announced by ES Cell International Pte. Ltd. (Melbourne, Australia) and the US National Institutes of Health (NIH, Bethesda, MD, USA). ES Cell has agreed to the NIH's research use of ES Cell's six existing stem cell lines. These meet the stem cell criteria articulated by US President Bush in August 2001.

In compliance with the NIH guidelines for the transfer of research materials, this agreement permits NIH scientists to freely publish the results of their research. The NIH will retain its ownership to any new intellectual property that might arise from the conduct of research in this area. In addition, the agreement governs the transfer of cell lines to individual laboratories with minimal administration.

ES Cell will retain commercial rights to its materials and will receive a fee to cover its handling and distribution expenses in supplying the cell lines. Furthermore, ES Cell has agreed to make stem cell lines available for use by nonprofit institutions that receive grants from the NIH under the same terms and conditions as those available to NIH scientists, provided these institutions enter into a separate written agreement
with ES Cell.

We are very pleased with this agreement for our scientists who are interested in pursuing research on human embryonic stem cells. It will allow science to move forward freely in
an important and promising field. The cell lines being offered are genetically diverse and as such will expand opportunities for researchers to explore important differences among cell lines, said Ruth Kirschstein, M.D., acting director of the NIH.

ES Cell is a regenerative medicine company focusing on developing therapeutic products from human embryonic stem (hES) cells. ES Cell funds research collaborations with the Monash Institute of Reproduction and Development (Australia), the National University of Singapore (Singapore), Hadassah Medical Organization (Israel), and the Hubrecht Laboratory (The Netherlands).




Related Links:
ES Cell
NIH

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
23 May 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
23 May 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
23 May 2002  |   BioResearch